| 영문 | aldosterone | 한글 | 알도스테론 |
|---|---|---|---|
| 설명 | 콩팥 위에 있는 작은 삼각형의 기관인 부신의 겉질에서 분비되는 호르몬. 체내의 물과 전해질의 균형에 기여한다. 신장에 작용해서 물과 나트륨의 흡수를 촉진하고 칼륨을 분비하게 한다. 즉 이 호르몬의 작용에 의하여 체내의 물과 나트륨의 양은 증가하고 칼륨의 양은 감소한다. 콩팥에서 혈류와 혈압을 감지하는 세포인 치밀반점(macula densa)과 토리곁세포(JG Cell)에서 혈류와 혈압의 저하가 있을 경우에 레닌(renin)이라는 물질이 분비된다. 이 레닌이라는 물질은 혈중에 존재하는 안지오텐시노겐이라는 물질을 안지오텐신 I으로 변화시키고 이 물질은 안지오텐신 I 전환효소에 의해서 안지오텐신 II라는 물질로 된다. 이 물질은 강력하게 혈관을 수축시키고 이로 인해서 혈압이 올라가는 동시에 부신을 자극하여 알도스테론을 분비하게 한다. 이 레닌-안지오텐신-살도스테론의 체계는 몸속의 혈압이 떨어지거나 혈액의 양이 줄어드는 경우에 작용해서 혈압을 올리는 작용을 한다.  |
||
| antag | antagonist |
|---|---|
| CA | anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can... |
| FAA | folic acid antagonist; formaldehyde, acetic acid, alcohol |
| RAA | Renin-Angiotensin-Aldosterone |
| AER | abduction/external rotation; acoustic evoked response; acute exertional rhabdomyolysis; agranular en... |
| A | Aldosterone |
|---|---|
| ALD | Aldosterone |
| ALDO | Aldosterone |
| APA | Aldosterone Producing Adenoma |
| ASR | Aldosterone Secretion Rate |
| aldosterone antagonist | An agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents, e.g., spironolactone, are useful in treating the hypertension of primary hyperaldosteronism, or the sodium retention of secondary hyperaldosteronism. (05 Mar 2000) |
|---|---|
| aldosterone antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of aldosterone. (12 Dec 1998) |
| aldosterone | <endocrinology, hormone> A steroid hormone produced by the adrenal cortex, that controls salt and water balance in the kidney. Abnormally high levels of this hormone cause sodium retention, high blood pressure, heart rhythum irregularities and possibly paralysis (18 Nov 1997) |
|---|---|
| receptors, aldosterone | Cytoplasmic proteins that specifically bind aldosterone and mediate its cellular effects. The aldosterone-bound receptor acts in the nucleus to regulate the transcription of specific segments of DNA. (12 Dec 1998) |
| renin-angiotensin-aldosterone system | The hormones, renin, angiotensin, and aldosterone work together to regulate blood pressure. A sustained fall in blood pressure causes the kidney to release renin. This is converted to angiotensin in the circulation. Angiotensin then raises blood pressure directly by arteriolar constriction and stimulates adrenal gland to produce aldosterone which promotes sodium and water retention by kidney, such that blood volume and blood pressure increase. (05 Mar 2000) |
| hormone, aldosterone | Hormone produced by the outer portion (cortex) of the adrenal gland that regulates the balance of water and electrolytes (ions such as potassium and sodium) in the body. Aldosterone encourages the kidney to excrete potassium into the urine and to retain sodium, thereby retaining water. Aldosterone is classified as a mineralocorticoid hormone. (12 Dec 1998) |
| antagonist | <pharmacology> A substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response. Origin: Gr. Antagonistes = an opponent (18 Nov 1997) |
| associated antagonist | One of two muscles or groups of muscles which pull in nearly opposite directions, but which, when acting together, move the part in a path between their diverging lines of action. (05 Mar 2000) |
| beta-adrenoreceptor antagonist | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| calcium antagonist | calcium channel-blocking agent |
| calcium channel antagonist | <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools. Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms. Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent. (12 May 2002) |
| mixed opioid agonist-antagonist | <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type. (13 Nov 1997) |
| competitive antagonist | An antimetabolite. (05 Mar 2000) |
| muscarinic antagonist | Drugs which bind with muscarinic cholinergic receptors but do not activate them, thus preventing access to acetylcholine; examples include atropine, scopolamine, propantheline, and pirenzepine. (05 Mar 2000) |
| H2 antagonist | <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells. Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers. Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac). (27 Sep 1997) |
| insulin antagonist | Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin. (09 Oct 1997) |
| oestrogen antagonist | <pharmacology> A drug or compound which inhibit or antagonise the action or biosynthesis of oestrogen. Tamoxifen also has agonist or stimulatory actions as well as blocking effects. There are also selective oestrogen-receptor modulators (SERMs). For example, raloxifene (trade name Evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. (12 May 2002) |
Synonyms : Antagonists, Aldosterone
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|